Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice


Multiple sclerosis (MS) is an autoimmune disease leading to the destruction of myelin with consequent axonal degeneration and severe physical debilitation. The disease can be treated with immunosuppressive drugs that alleviate the symptoms and retard disease aggravation. One such drug in clinical use is glatiramer acetate (Copaxone). The non-psychotropic immunosuppressive cannabinoid compound cannabidiol (CBD) has recently been shown to have beneficial effects on experimental autoimmune encephalomyelitis (EAE). The aim of our study was to compare the efficacy of CBD and standardized extracts from a CBD-rich, ∆9-THClowCannabis indica subspecies (Avidekel) with that of Copaxone. Our data show that CBD and purified Avidekel extracts are as efficient as Copaxone to alleviate the symptoms of proteolipid protein (PLP)-induced EAE in SJL/J mice. No synergistic effect was observed by combining CBD or Avidekel extracts with Copaxone. Our data support the use of Avidekel extracts in the treatment of MS symptoms.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5





Central nervous system


Experimental autoimmune encephalomyelitis


Multiple sclerosis


Proteolipid protein


  1. Arnon R (1996) The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol Lett 50:1–15

    Article  CAS  PubMed  Google Scholar 

  2. Burstein S (2015) Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem 23:1377–1385

    Article  CAS  PubMed  Google Scholar 

  3. Gallily R, Yekhtin Z, Hanuš L (2015) Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol. Pharmacol Pharmacy 6:75–85

    Article  CAS  Google Scholar 

  4. Giacoppo S, Bramanti P, Mazzon E (2017) Sativex in the management of multiple sclerosis-related spasticity: an overview of the last decade of clinical evaluation. Mult Scler Relat Disord 17:22–31

    Article  PubMed  Google Scholar 

  5. Hemmer B, Kerschensteiner M, Korn T (2015) Role of the innate and adaptive immune responses in the course of multiple sclerosis. Lancet Neurol 14:406–419

    Article  CAS  PubMed  Google Scholar 

  6. Holm S (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6:65–70

    Google Scholar 

  7. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 97:9561–9566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. McCarthy DP, Richards MH, Miller SD (2012) Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol Biol 900:381–401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rahimi A, Faizi M, Talebi F, Noorbakhsh F, Kahrizi F, Naderi N (2015) Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience 290:279–287

    Article  CAS  PubMed  Google Scholar 

  10. Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple Sclerosis N Engl J Med 378:169–180

    CAS  PubMed  Google Scholar 

  11. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1:242–248

    Article  CAS  PubMed  Google Scholar 

  12. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R (2008) Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology 54:244–249

    Article  CAS  PubMed  Google Scholar 

Download references


The authors would like to thank Dr. Ronit Sionov for her valuable editorial assistance.

Author information



Corresponding author

Correspondence to Ruth Gallily.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gallily, R., Yekhtin, Z. Avidekel Cannabis extracts and cannabidiol are as efficient as Copaxone in suppressing EAE in SJL/J mice. Inflammopharmacol 27, 167–173 (2019). https://doi.org/10.1007/s10787-018-0536-3

Download citation


  • Avidekel extracts
  • Cannabidiol (CBD)
  • Cannabis
  • Experimental autoimmune encephalomyelitis (EAE)
  • Immunosuppression